NEW YORK, June 13, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Tempus AI, Inc. (“Tempus” or the “Company”)  (NASDAQ: TEM) in the United States District Court for the Northern District of Illinois on behalf of all persons and entities who purchased or otherwise acquired Tempus securities between August 6, 2024 and May 27, 2025, both dates inclusive (the “Class Period”). Investors have u ...

SAN DIEGO, June 13, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Tempus AI, Inc. (NASDAQ: TEM) common stock between August 6, 2024 and May 27, 2025. Tempus purports to be provide Artificial Intelligence ("AI") enabled precision medicine solutions. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegations: Robbins LLP is Investigating Allegatio ...

MIAMI, June 13, 2025 (GLOBE NEWSWIRE) -- The following statement is being issued by Shamis & Gentile, P.A: To: All persons or entities who purchased or otherwise acquired Tempus AI, Inc. (“Tempus” or the “Company”) (NASDAQ:TEM) common stock between August 6, 2024 and May 27, 2025, inclusive. You are hereby notified that the class action lawsuit Shouse v. Tempus AI. Inc., et al., Case No. 1:25-cv-06534 has been commenced in the United States District Court for the Northern District of Illinois. For more info ...

Key Takeaways TEM signed a $200M three-way deal with AZN and Pathos to build a multimodal oncology foundation model. The partnership lifts TEM's total remaining contract value to over $1B as of April 2025. TEM also expanded ties with ILMN to advance molecular profiling across all major disease areas.ForTempus AI (TEM) , expanding partnerships with existing customers across each of its product lines is key to its growth. In April 2025, the AI-driven precision medicine company extended its collaboration wit ...

SAN DIEGO, June 13, 2025 /PRNewswire/ -- Robbins LLP informs stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Tempus AI, Inc. (NASDAQ: TEM) common stock between August 6, 2024 and May 27, 2025.  Tempus purports to be provide Artificial Intelligence ("AI") enabled precision medicine solutions.For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.The Allegations: Robbins LLP is Investigating Allegations th ...

Key Takeaways TEM jumped 12.5% in early June, fueled by new product launches and strong investor response. The $200M deal with AstraZeneca boosts TEM's role in AI-driven oncology diagnostics and drug discovery. Despite revenue growth and tech advances, TEM remains unprofitable and trades at a premium to peers.Tempus AI (TEM) surged 12.5% in the first week of June, outperforming the broader market and the benchmarks by a wide margin. This rally came largely on the heels of investors’ positive reaction to t ...

Tempus AI, Inc. (NASDAQ: TEM ) is a technology company that enables precision medicine. Its core business is genomics and data services, but recently, it has expanded its vision into AI for healthcare applications. While this has resulted in impressive growth, aMy name is Myriam Hernandez Alvarez. I received the Electronics and Telecommunication Engineering degree from the Escuela Politecnica Nacional, Quito, Ecuador, the M.Sc. degree in computer science from Ohio University, Athens, OH, USA, a graduate deg ...

股价表现 - Tempus AI股价在6月初呈现反弹趋势 从上周五收盘至本周一上午11:37 ET上涨12% [2] - 此前一周该股曾下跌11 8% 当前反弹显示市场情绪改善 [1] 机构观点 - TD Cowen维持对Tempus AI的买入评级 目标价62美元 认为Spruce Point的做空报告多数问题已被市场认知或存在夸大 [4][5] - 分析师指出做空报告中部分问题仍需进一步调查 但整体影响有限 [4] 公司动态 - Tempus AI上周末发布两项未具体说明的公告 可能对股价产生积极影响 [1] - Spruce Point做空报告质疑公司与阿斯利康合作关系的真实性及财务报告准确性 [5] 投资建议 - 现有股东可关注TD Cowen维持评级的积极信号 但潜在投资者建议等待8月2025年Q2财报公布后再做决策 [6] - 市场需观察Tempus AI与阿斯利康合作等事项的后续进展 [5][6]

公司调查事件 - 律师事务所Pomerantz LLP正在调查Tempus AI Inc可能存在的证券欺诈或其他非法商业行为 [1] - 调查涉及公司及其部分高管和/或董事 [1] Spruce Point报告指控 - Spruce Point Capital Management发布报告指出Tempus存在"激进的会计和财务报告"问题 [3] - 报告质疑公司董事会成员和其他高管与财务重述问题公司有关联 [3] - 报告认为公司与阿斯利康(AstraZeneca)和Pathos AI的关键战略合作伙伴关系及交易公告值得审查 [3] 市场反应 - 报告发布后Tempus股价单日下跌12.67美元(跌幅19.23%)至53.20美元/股 [3] 律师事务所背景 - Pomerantz LLP在证券集体诉讼领域具有领先地位 [4] - 该律所已为客户追回多笔数百万美元的赔偿金 [4]

Key Takeaways Tempus AI cuts first-quarter 2025 adjusted EBITDA loss by $27.8 million, showing strong cost discipline. Tempus AI's revenues grew 75.4% in the first quarter, but gross profit rose even faster at 99.8%. Tempus AI stock climbed 71.8% year to date, beating the industry gains of 22.9%.Tempus AI (TEM) is currently in its 10th year of business and on track to hit a long-anticipated milestone. In its first-quarter 2025 earnings report, the AI-driven healthcare company guided full-year adjusted EBI ...